Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Internationally accepted pharmaceutical GDP regulations stipulate that distributors of pharmaceutical products and warehouses must align their operations with the specified standards
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Commits to plant 5000 trees in phase 1 with its partner SankalpTaru Foundation
First advanced hybrid closed-loop insulin pump system in India features automatic insulin delivery, automatic correction boluses, and bluetooth connectivity
Subscribe To Our Newsletter & Stay Updated
